- Home
- BGI vs BOLT Comparison
BGI vs BOLT Comparison
Compare BGI & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- BOLT
- Stock Information
- Founded
- BGI 1879
- BOLT 2015
- Country
- BGI Canada
- BOLT United States
- Employees
- BGI N/A
- BOLT N/A
- Industry
- BGI
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- BOLT Health Care
- Exchange
- BGI Nasdaq
- BOLT Nasdaq
- Market Cap
- BGI 15.7M
- BOLT 16.8M
- IPO Year
- BGI 2005
- BOLT 2021
- Fundamental
- Price
- BGI $0.61
- BOLT $5.63
- Analyst Decision
- BGI
- BOLT Buy
- Analyst Count
- BGI 0
- BOLT 3
- Target Price
- BGI N/A
- BOLT $50.00
- AVG Volume (30 Days)
- BGI 160.9K
- BOLT 16.8K
- Earning Date
- BGI 07-25-2025
- BOLT 08-19-2025
- Dividend Yield
- BGI N/A
- BOLT N/A
- EPS Growth
- BGI N/A
- BOLT N/A
- EPS
- BGI N/A
- BOLT N/A
- Revenue
- BGI $124,446,731.00
- BOLT $3,638,000.00
- Revenue This Year
- BGI N/A
- BOLT N/A
- Revenue Next Year
- BGI N/A
- BOLT $13.62
- P/E Ratio
- BGI N/A
- BOLT N/A
- Revenue Growth
- BGI N/A
- BOLT N/A
- 52 Week Low
- BGI $0.57
- BOLT $5.20
- 52 Week High
- BGI $2.95
- BOLT $14.36
- Technical
- Relative Strength Index (RSI)
- BGI 22.36
- BOLT 43.84
- Support Level
- BGI $0.82
- BOLT $5.50
- Resistance Level
- BGI $0.78
- BOLT $5.94
- Average True Range (ATR)
- BGI 0.08
- BOLT 0.35
- MACD
- BGI -0.02
- BOLT -0.04
- Stochastic Oscillator
- BGI 10.54
- BOLT 21.25
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.